PACB Pacific Biosciences of California, Inc.
PACB Pacific Biosciences of California, Inc.
Healthcare · Medical Devices
Desk view
Market read
POC $1.32 · VWAP $1.82 · -4.8% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
2 watchlists
PACB Price Structure
Loading timeframes…
Peers
Every watchlist PACB belongs to, members best 30-day change first — PACB highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
@ibb
Reported the quarter ending 2026-06-30: revenue $39M, diluted EPS -$0.14, net income -$45M (SEC filing). Across the print the stock moved -18.8% (close before → first close after).
full note →Against street estimates
How PACB's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about PACB from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled today · Oct 17
- Pacific Biosciences of California, Inc. Share Price Live Today – NASDAQ:PACB Stock Price, Chart, News, History
- Pacific Biosciences of California, Inc. - Common Stock (Nasdaq:PACB) Stock Quote
- Press Releases - PacBio
- pacb-20260730 - SEC.gov
- PacBio Announces Second Quarter 2026 Financial Results
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
PACB research tape
17 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.